Evidence map›Paper›PMID 40595122›Full record

ArticleScientific reports2025

Functional immune reconstitution after allogeneic hematopoietic stem cell transplantation in myeloablative and non-myeloablative conditioned patients.

Patrick Terrence Brooks, Lia Minculescu, Rebecca Svanberg Teglgaard, Hans Jakob Hartling, Jose Antonio Salado-Jimena, Lone Smidstrup Friis, Brian Kornblit, Ida Schjødt, Søren Lykke Petersen, Niels Smedegaard Andersen and 6 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Patrick Terrence BrooksDepartment of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet Inge Lehmanns Vej 7, Copenhagen, 2100, Denmark. patrick.terrence.brooks@regionh.dk.
Lia MinculescuDepartment of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet Inge Lehmanns Vej 7, Copenhagen, 2100, Denmark.
Rebecca Svanberg TeglgaardDepartment of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet Inge Lehmanns Vej 7, Copenhagen, 2100, Denmark.
Hans Jakob HartlingDepartment of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet Inge Lehmanns Vej 7, Copenhagen, 2100, Denmark.
Jose Antonio Salado-JimenaDepartment of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet Inge Lehmanns Vej 7, Copenhagen, 2100, Denmark.
Lone Smidstrup FriisDepartment of Hematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Brian KornblitDepartment of Hematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Ida SchjødtDepartment of Hematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Søren Lykke PetersenDepartment of Hematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Niels Smedegaard AndersenDepartment of Hematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Susanne Dam NielsenDepartment of Infectious Diseases, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Jens LundgrenDepartment of Infectious Diseases, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Hanne Vibeke MarquartDepartment of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet Inge Lehmanns Vej 7, Copenhagen, 2100, Denmark.
Lars Klingen GjaerdeDepartment of Hematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Henrik Sengeløv *Department of Hematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Sisse Rye Ostrowski *Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet Inge Lehmanns Vej 7, Copenhagen, 2100, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a treatment modality for several hematological and immune-driven diseases. A conditioning regimen precedes transplantation. These comprise myeloablative (MA) conditioning consisting of chemotherapeutics often in combination with high-dose total body irradiation (TBI), while non-myeloablative (NMA) conditioning regimens use reduced dosage of chemotherapy and TBI allowing allo-HCT to patients who would otherwise not be eligible for treatment. While cellular immune reconstitution in allo-HCT patients has been well studied, differences between MA and NMA conditioned patients including the functional status of the immune system post-transplantation remains unclear. Seventy-seven patients undergoing allo-HCT were included in the main study, only including patients receiving peripheral blood stem cell grafts, no ATG treatment and no other GVHD prophylaxis than tacrolimus + methotrexate or cyclosporine + MMF + sirolimus (median age 59; IQR: 48-65). The cohort consisted of 34 patients receiving MA conditioning and 43 NMA conditioned patients. As a proxy for post-transplantation immune function, we analyzed stimulated cytokine release patterns in whole-blood samples from MA and NMA patients before and after transplantation alongside major immune cell phenotypes and T cell chimerism on day 28 after transplantation. Notably, among patients receiving grafts from peripheral blood apheresis, MA patients exhibited higher T cell counts, and elevated CD3/CD28-stimulated cytokine release compared to NMA patients. Assessment of associations between cytokine release and immune cell concentration associations indicated that variation in T cell or other immune cell concentrations between the cohorts could not account for differences in CD3/CD28-stimulated cytokine release. Meanwhile, LPS- and R848-stimulated cytokine release was associated with innate immune cell subtypes. A secondary study amongst MA conditioned patients further revealed that those who received fludarabine and treosulfan (n = 35) had higher T cell concentration and stimulated immune function compared to patients receiving more intense MA regimens (n = 15). These findings highlight the complex impact conditioning has on immune function after allo-HCT. Further analyses of T cell compartments and myeloid/lymphoid innate cells are needed to further understand the functional differences observed between conditioning groups and the potential impact on clinical outcomes.

Indexed as

Hematopoietic Stem Cell TransplantationImmune ReconstitutionTransplantation ConditioningAgedCytokinesFemaleGraft vs Host DiseaseHumansMaleMiddle AgedMyeloablative AgonistsTransplantation, HomologousWhole-Body IrradiationCytokinesMyeloablative AgonistsBone marrow transplantationConditioningHematopoietic stem cellsImmune functionImmune stimulationTruCulture

Identifiers

PMID40595122
PMCPMC12215635

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.